NCT06339554View on ClinicalTrials.gov

Alectinib-induced Endocrine Toxicity

CompletedOBSERVATIONAL
Enrollment

98

Participants

Timeline

Start Date

October 12, 2018

Primary Completion Date

October 30, 2023

Study Completion Date

October 30, 2023

Conditions
NSCLC Stage IV
Interventions
DRUG

Alectinib 150 MG [Alecensa]

First line treatment for cohorts A and B

Trial Locations (1)

00168

Fondazione Policlinico Gemelli IRCCS, Rome

All Listed Sponsors
lead

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

OTHER

NCT06339554 - Alectinib-induced Endocrine Toxicity | Biotech Hunter | Biotech Hunter